Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity

Journal of Infectious Diseases

Volumn 169, Issue 6, 1994, Pages 1346-1350

  De Jong, Menno D ^a,b,c,d,e,f   Loewenthal, Mark ^a,b,c,d,e,f   Boucher, Charles A B ^a,b,c,d,e,f   Van Der Ende, Ineke ^a,b,c,d,e,f   Hall, David ^a,b,c,d,e,f   Schipper, Pauline ^a,b,c,d,e,f   Imrie, Allison ^a,b,c,d,e,f   Weigel, Hugo M ^a,b,c,d,e,f   Kauffmann, Robert H ^a,b,c,d,e,f   Koster, Roel ^a,b,c,d,e,f   Seville, Peter ^a,b,c,d,e,f   Rocklin, Ross ^a,b,c,d,e,f   Cooper, David A ^a,b,c,d,e,f   Lang, Joep M A ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPENIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMAN; NEVIRAPINE; PYRIDINES; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; ZIDOVUDINE;

EID: 0028307861     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.6.1346     Document Type: Article

References (13)

1. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
2. Koup RA, Merluzzi VJ, Hargrave K.D. et al. Inhibition ofhuman immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiaze-pinone BI-RG-587. J Infect Dis 1991;163:966-70.
3. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990;343:470-4.
4. Goldman ME, Nunberg JH, O'Brien JA, et al. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-7.
5. Duwueke TJ, Poppe SM, Romero DL. et al. U-90152, a potent inhibitor ofhuman immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993;37:1 127-31.
6. Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35: 305-8.
7. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-82.
8. Cheeseman SH, Nevirapine (nvp) alone and in combination with zidovudine (zdv): Safety and activity [abstract]. In: Program and abstracts: VIII International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992.
9. Richman DD, Loss of nevirapine activity associated with the emergence of resistance in clinical trials [abstract]. In: Program and abstracts: VIII International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland. 1992:B183.
10. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697, 661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72.
11. Boucher CAB, Van Leeuwen R, Kellam P, et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type I isolates. Antimicrob Agents Chemother 1993;37:1525-30.
12. Larder BA. 3'-azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type I resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-9.
13. Havlir D. Antiviral activity of nevirapine at 400 mg in p24 antigen-positive adults [abstract]. In: Program and abstracts: IX International Conference on AIDS/1V STD World Congress (Berlin). London: Wellcome Foundation. 1993:69.